Streetbeat News

Products Services

MU

Micron Technology, Inc. has announced the commencement of volume production of its HBM3E solution, leading to an increase in its stock price.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:47 pm

BABA

NVDA

RIVN

TSLA

Cryptocurrencies trade mixed as Dogecoin mirrors 2023 bull market patterns, and Bitcoin's potential post-halving correction could target $40K. Rivian rebounds in premarket trading. Analysts predict a pause in US stock rally and discuss potential impacts of a second Trump presidency. International tensions rise with US-China relations and covert operations in Ukraine. Tech sector sees Nvidia's upside potential and Alibaba's optimism, while electric vehicle companies like Tesla and Rivian make headlines. Broadcom nears a strategic sale, and financial deals include Ant Group's acquisition of Credit Suisse's China unit.

Portfolio Pulse from Akanksha Bakshi

February 26, 2024 | 1:46 pm

MOD

Modine (NYSE:MOD) has announced the acquisition of Scott Springfield Manufacturing, a leading air handling unit manufacturer, to enhance its data center technology portfolio and indoor air quality offerings. This strategic move aims to expand Modine's product line and customer base in high-growth markets such as hyperscale data centers and healthcare. The acquisition, valued at approximately $190 million, is expected to close in the first quarter of 2024 and is anticipated to be immediately accretive to earnings. Scott Springfield's fiscal 2023 revenue is expected to exceed $100 million.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:42 pm

GILD

Gilead Sciences, Inc. (GILD) announced its participation in CROI 2024, presenting new data from its antiviral research programs, including studies on HIV, COVID-19, and viral hepatitis. Key highlights include findings on Biktarvy and investigational regimens like lenacapavir plus bictegravir, and the impact of Veklury on COVID-19 mortality. The presentations underscore Gilead's commitment to biomedical innovation and addressing global viral disease challenges.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:39 pm

ENLV

Enlivex has been granted regulatory authorization by Israel's Health Ministry to begin a Phase 1/2 trial for Allocetra in treating knee osteoarthritis. This marks a significant step forward in the development of Allocetra, potentially impacting its future market positioning and investor interest in ENLV.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:36 pm

LIXT

LIXTE Biotechnology has entered into an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI) for immune oncology. This agreement allows LIXTE to develop and commercialize a specific patented technology in the field of immune oncology, potentially enhancing its product pipeline and positioning in the biotechnology sector.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:34 pm

CTCX

Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company, announced the completion of their Gold Limited Edition Exclusive product for launch in March 2024, along with the development of 9 other skincare products for release in Spring and Summer 2024. These products, including a men's line and haircare products, utilize the Carmell SecretomeTM technology and a novel micellar nanoparticle formulation, avoiding harmful excipients. Manufactured in-house at their Pittsburgh facility, Carmell's products meet and surpass current and proposed regulatory standards.

Portfolio Pulse from Happy Mohamed

February 26, 2024 | 1:33 pm

NRXP

NRx Pharmaceuticals announced the launch of HOPE Therapeutics at the BIO CEO & Investor Conference 2024, proposing to award 50% of founding shares to current shareholders along with a royalty coupon, contingent on board approval. The dividend is tied to a covenant against short selling NRx stock. HOPE plans to have ketamine supplies ready for shipment under 503a pharmacy regulations by July 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:32 pm

ALVO

Alvotech's stock price increased following the announcement that the FDA has approved its arthritis treatment. This approval marks a significant milestone for Alvotech, potentially opening up a large market for its newly approved medication.

Portfolio Pulse from Luke J Jacobi

February 26, 2024 | 1:30 pm

BOF

BranchOut Food Inc. (NASDAQ:BOF), a food technology company, announced an expansion of its relationship with the nation's largest warehouse club due to exceptional sales of its Pineapple Chips in California. The expansion includes two new orders worth approximately $900,000 for Q3 2024, extending the product's reach to the Northern California Region and seven additional states in the Southeast. This follows a successful product launch in the Bay Area and Southern California regions.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:24 pm